Study of Reminder-Focused Positive Psychiatry for Adolescents Aged 11 to 15 with Posttraumatic Stress Disorder PTSD

What this Trial Is About

Posttraumatic stress disorder PTSD is a common neuropsychiatric condition affecting children and is linked to increased neurovascular inflammation, suicidality, and later mental health issues. Researchers are evaluating the clinical and biomolecular effects of Reminder Focused Positive Psychiatry RFPP in adolescents aged 11 to 15 with PTSD. This trial assesses how RFPP influences core PTSD symptoms, trauma reactivity, wellbeing, vascular function, inflammation, and gene expression compared to a control group. Participants will be randomly assigned to one of two groups the RFPP group intervention or an attentional control group receiving relaxation therapy. Both groups undergo telehealth sessions twice weekly for six weeks. The RFPP intervention focuses on improving emotional regulation and adaptive coping with trauma reminders, while the control group receives progressive muscle relaxation, education about PTSD, and supportive psychotherapy. Parents also participate weekly for six weeks, receiving psychoeducation or group process interventions. Throughout the study, adolescents and their parents will complete neuropsychiatric assessments at baseline, 3, 6, and 24 weeks. Biological markers including vascular function, inflammation markers, and stress-related gene expression will be measured at baseline and after six weeks. The main outcomes include changes in PTSD symptoms, trauma reactivity, wellbeing, biological markers, and parent-child interaction quality. The total study duration for participants is 24 months, including long-term follow-up assessments.

Biomolecular Characteristics of Reminder-Focused Positive-Psychiatry